14The Fourth Medium-Term Plan positions “Products and manufacturing plants that are continuously chosen” as a priority theme. For Maruho’s further advancement, it is crucial to make our plants and pharmaceuticals continuously trusted and chosen by everyone, including patients, medical professionals, and business partners. We are working to accumulate production know-how and expand functions to provide safe and reliable drugs while aiming to establish a flexible and efficient production system capable of responding to the increasingly diverse needs of customers.Maruho has established a solid production system composed of four bases: Hikone Plant and Nagahama Plant, our main plants for drug formulation and preparation, filling, packaging, and labelling, and the two Group companies Tateyama Pharmaceutical Factory Co., Ltd. and Roman Industries Co., Ltd. By managing and operating the Group’s resources, including production plans and maintenance data of each production site, in an integrated manner, we aim to stabilize quality and optimize the production system. In contrast to the recent trend in the pharmaceutical industry of outsourcing manufacturing, Maruho continues to maintain an integrated production system for its main products, from the APIs to final products. When assigning a part of the production processes to our partner companies, we are enhancing our involvement in the manufacturing processes and GMP* of the partners.* GMP (Good Manufacturing Practice): A ministerial order concerning standards for manufacturing control and quality control of pharmaceuticals and quasi-pharmaceutical productsMaruho is committed to the continuous quality improvement of drugs and product modification, as well as the establishment of a flexible production system, with the aim of satisfying a wide range of diverse customer needs.Flexible production system satisfying diverse needsMaruho’s corporate mission is “to contribute to better health for people all over the world.” To this end, ensuring the quality of pharmaceutical products and establishing a stable supply system is one of our highest-priority tasks in business management. Since the completion of the Hikone Plant in 1972, to provide a stable supply of high-quality topical drugs, we have been actively investing management resources to strengthen our production bases and production systems. Through production of topical drugs, which we boast the top-class production volume in Japan, we have aimed to ensure safety and security in our product supply and improve the QOL of patients.Stable supply realized by four manufacturing plants, utilizing Group resourcesAiming for “Products and manufacturing plants that are continuously chosen”ManufacturingOne of the best integrated production systems in Japan,pursuing trust from patients
元のページ ../index.html#16